A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia

Update Il y a 4 ans
Reference: ISRCTN44218911

Woman and Man

Extract

Not provided at time of registration


Inclusion criteria

  • Schizophrenia

Links